Methylone demonstrates improvement in PTSD symptoms in Phase 2 study
The Brown University Psychopharmacology Update April 30, 2026 Peer reviewed DOI: 10.1002/pu.31448 via OpenAlex
Summary
Four weekly doses of TSND‐201, an analog of MDMA, significantly reduced symptoms of post-traumatic stress disorder (PTSD) compared to placebo. The treatment was associated with generally mild to moderate adverse effects, and there were no significant instances of suicidal ideation reported.
Study at a glance
| Design | Phase 2 study |
|---|---|
| Population | individuals with post-traumatic stress disorder (PTSD) |
| Key finding | TSND‐201 resulted in significant improvement in PTSD symptoms compared to placebo. |
Abstract
Four weekly doses of TSND‐201 (methylone), an analog of 3,4 methylenedioxymethamphetamine (MDMA), resulted in significant improvement relative to placebo in reducing symptoms of post‐traumatic stress disorder (PTSD), a Phase 2 study has found. Treatment‐emergent adverse events associated with TSND‐201 were generally mild to moderate in severity, with no significant suicidal ideation. Study results were published online Feb. 18, 2026, in JAMA Psychiatry .